Quinapril
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
ACE Inhibitors | Quinapril | 2.5-10mg PO Q24H | Administer Anytime During HD; Post HD if Hypotensive |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
438 | 30 (active drug); 96% (quinaprilat) | 1-2 (active drug); 3 (quinaprilat) | 6-15 | 97 | 1.5 | 15.4 | 12 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00881
- Tsuruoka S, Kitoh Y, Kawaguchi A, et al. Clearance of imidapril, an Angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril. Journal of clinical pharmacology. 2007; 47(2):259-63.
- Zheng S, Nath V, Coyne D. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. American journal of nephrology. 2007; 27(5):522-9.